SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Robloxs quarterly results beat some estimates, but the weaker user metrics and outlook for a year-over-year decline in fourth-quarter bookings sparked a sharp selloff. Traders are largely focused on slowing engagement and monetization, while some see the drop as a buying opportunity.

Albemarle Corp. engages in the development, manufacture, and marketing of chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, transportation, pharmaceuticals, crop production, food-safety, and custom chemistry services. It operates through the following segments: Energy Storage, Specialties, and Ketjen. The Energy Storage segment develops and manufactures a broad range of basic lithium compounds, including lithium carbonate, lithium hydroxide, and lithium chloride. The Specialties segment focuses on optimizing a portfolio of bromine and specialized lithium solutions. The Ketjen segment consists of clean fuels technologies, fluidized catalytic cracking catalysts and additives, and performance catalyst solutions, which is primarily composed of organometallics and curatives. The company was founded in 1993 and is headquartered in Charlotte, NC.

Albemarle Corp.

Albemarle Corp

Albemarle is under pressure as falling lithium spot and futures prices weigh on sentiment ahead of earnings, with traders questioning where prices and the stock will bottom. Some see the selloff as an opportunity given longer-term battery and storage demand, while others expect further downside and want clearer guidance on lithium-price recovery.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas earnings beat and raised outlook, alongside renewed interest in identity security for AI agents, fueled a sharp rally. Traders are divided between seeing durable AI-security demand and index inclusion as support and warning that the valuation is stretched, leaving shares vulnerable to profit-taking and a pullback.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

CleanSpark is under pressure alongside bitcoin miners and AI-infrastructure names, with traders citing macro and interest-rate concerns, financing risk, and the sectors sharp selloffeven as Bitcoin has held up at times. The debate centers on whether its Meta data-center lease and bitcoin holdings justify buying the dip or whether debt, execution risks, and weak share performance outweigh that potential; some traders also blame heavy short interest.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Updated Phase 3 VIKTORIA-1 subgroup data in PIK3CA-mutant breast cancer is driving discussion, with traders highlighting the gedatolisib regimens efficacy versus the comparator. The positive clinical reaction is tempered by debate over the pending FDA label expansion and whether Celcuity can translate its approved drug into meaningful commercial uptake.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

Reports of SpaceX pursuing spectrum and access to U.S. cell sites have fueled concern that Starlink Mobile could become a competitor to AT&T and other wireless carriers. Traders debate whether the threat is material or years away given the cost and complexity of building a network; many view the telecom selloff as an overreaction, despite AT&Ts strong results and higher outlook.

Nu Holdings Ltd. is a holding company, which engages in the provision of digital banking services. The company was founded by David Vélez Osorno, Cristina Helena Zingaretti Junqueira, and Adam Edward Wible on February 26, 2016 and is headquartered in São Paulo, Brazil.

Nu Holdings Ltd - Ordinary Shares Class A

Nu Holdings Ltd

Brazils election outcome has sparked a broad selloff in Brazilian-linked stocks, with traders concerned about political and economic risk weighing on Nus Brazil-heavy business. Many investors argue the reaction is an overreaction because the companys fundamentals remain intact, while others expect continued volatility.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader tech and semiconductor selloff as investors question whether heavy AI infrastructure spending will generate adequate returns, with weak Intel guidance and Amazons spending outlook adding to the pressure. Traders are divided between viewing the pullback as an AI-bubble warning and treating it as a buying opportunity, citing continued chip demand and Nvidias business strength.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTXs breakout to fresh 52-week highs is drawing attention ahead of its expected earnings report, with traders also speculating about a possible buyout and short covering. The acquisition talk is unconfirmed; some traders instead point to BRIUMVIs growth and earnings expectations as support for the rally.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts strong quarterly results and accelerating Azure growth drew attention, but the post-earnings rally faded as traders weighed its planned bond sale and heavy AI infrastructure spending amid a broader tech selloff. The community is split between seeing Azure demand and cash generation as evidence the investments are paying off and worrying that rising funding needs could pressure returns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASPR NewswireNEW YORK, Oct. 29, 2026 NEW YORK, Oct. 29, 2026 /PRNewswire/ -- Pomerantz LLP is...

ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Erasca, Inc. (Erasca or the Company) (NASDAQ: ERAS) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERASPR NewswireNEW YORK, Oct. 22, 2026 NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is...

ERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud Lawsuit with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Erasca, Inc. (Erasca or the Company) (NASDAQ: ERAS) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder...

CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Erasca (ERAS) Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Erasca, Inc. (Erasca or the Company) (NASDAQ: ERAS) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been...

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP By Application Deadline Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol...

Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit

Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit Erasca, Inc. Investor Alert: Contact SBS by August 10, 2026 for Opportunity to Lead Securities Fraud Lawsuit PR Newswire LOS ANGELES, Aug. 10, 2026 LOS ANGELES, Aug. 10, 2026 /PRNewswire...

Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS

Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS Erasca, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ERAS PR Newswire LOS ANGELES, Aug. 10, 2026 LOS ANGELES, Aug. 10, 2026 /PRNewswire/ -- The...

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline

Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman...

Erasca 72 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Erasca, Inc. - ERAS

Kahn Swick & Foti, LLC (KSF) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Erasca, Inc. (Erasca or the Company) (NasdaqGS: ERAS...

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Erasca Inc

ERAS Stock Slumps Nearly 40% After-Hours: Fine Print In 'Positive' Cancer Trial Reveals Treatment-Related Death 

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>The death followed Grade 3 pneumonitis in a 66-year-old pancreatic cancer patient receiving a 24 mg dose.</li><li>ERAS-0015 showed strong early tumor response rates, including 62% in KRAS-mutant lung cancer.</li><li>Additional data from the Auroras-1 trial are expected in 2027, while results from its other candidate, ERAS-4001, are expected later this year.</li></ul>Shares of Erasca, Inc. (ERAS) plunged nearly 40% in extended trading on Monday after investors spotted a treatment-related death buried within safety disclosures, even as the company flagged strong early tumor response rates from a Phase 1 study of its experimental cancer therapy ERAS-0015.<a href="https://stocktwits.com/symbol/ERAS">ERAS stock</a> slid nearly 11% on Monday, logging its worst session in nearly eight months.&nbsp;<h2 class="st-heading-2">Treatment-Related Death Surfaces In ERAS Phase 1 Trial</h2>According to a fresh filing, one patient experienced Grade 3 pneumonitis that progressed to a treatment-related death. The patient was a 66-year-old male with metastatic pancreatic cancer receiving a 24 mg dose of ERAS-0015 who had pulmonary metastases and prior lung procedures before entering the study.&nbsp;The patient later discontinued treatment after developing pneumonitis one month after therapy initiation and later died following withdrawal of supportive care.<h2 class="st-heading-2">ERAS Cancer Trial Shows Strong Early Cancer Responses&nbsp;</h2>Alongside the safety update, Erasca reported strong early response signals from the company’s Auroras-1 study across KRAS-mutant cancers. In previously treated non-small cell lung cancer, ERAS-0015 showed a 62% tumor response rate at eight weeks, rising to 75% among patients who had already received immunotherapy and platinum chemotherapy. In pancreatic cancer, the therapy showed a 40% response rate at fourteen weeks, with most responding patients still on treatment at the time of analysis.The company also reported that all 14 evaluable patients showed large reductions in circulating tumor DNA levels. Based on these results, Erasca selected 24 mg and 32 mg once daily as the doses to move forward into expansion studies.&nbsp;Looking ahead, the company expects additional monotherapy expansion and combination dose-escalation data from the Auroras-1 study in the first half of 2027. Preliminary Phase 1 data for ERAS-4001, its pan-KRAS inhibitor program, is expected in the second half of this year.<h2 class="st-heading-2">RevMed Patent Claims Add Pressure&nbsp;</h2>Separately, Erasca disclosed in the new filing that it received a letter from the legal counsel for Revolution Medicines alleging that ERAS-0015 may infringe compositions claimed in a U.S. patent under the doctrine of equivalents. The letter also alleged possible trade-secret misappropriation from a third-party patent relating to ERAS-0015 and challenged comparisons between ERAS-0015 and RMC-6236 made in public disclosures.RMC-6236 is a cancer drug being developed by Revolution Medicines to treat tumors driven by KRAS mutations. Unlike older targeted therapies that focus on a single mutation, it works across multiple KRAS mutation types, which are common in cancers such as lung and pancreatic cancer. It is still in early-stage clinical testing.Revolution Medicines requested that Erasca cease manufacturing, using or selling ERAS-0015 outside Hatch-Waxman safe-harbor protections and stop making “untrue comparative statements.” However, Erasca said it believes the allegations are without merit and intends to contest them vigorously.<h2 class="st-heading-2">How Do Retail Traders Feel About ERAS?</h2>On Stocktwits, retail sentiment for ERAS slipped to ‘bearish’&nbsp; from ‘neutral’ levels from a day ago amid ‘extremely high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/eras_ss_png_c88c88c3a3.webp" alt="eras ss.png" width="980" height="152"><figcaption>ERAS sentiment and message volume as of April 28 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/docsamiles/message/651583972">said</a>, “Long-term effert on stock price depends on Erasca's relationship with FDA and whether a clinical hold is issued. Honesty and timeliness is paramount in FDA interactions.”<stembedurl>https://stocktwits.com/docsamiles/message/651583972</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/FDAvalid/message/651581652">said</a>, “The Reality Check: If a drug makes a patient "decide" to stop all care, the toxicity is the problem, not the patient. You aren't buying a dip; you're buying a bio-hazard.”<stembedurl>https://stocktwits.com/FDAvalid/message/651581652</stembedurl>ERAS stock has surged nearly 1,300% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lucid-stock-crash-retail-eye-saudi-pif-buyout/cZB8j0uRe5d">Lucid Stock Is Crashing Hard And Leaves Retail Wondering If Saudi PIF Buyout Is A Good Exit Strategy</a>

In this photo illustration, the Erasca logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ERAS Stock - Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Meanwhile, Revolution Medicines has alleged potential patent infringement and trade-secret issues related to ERAS-0015.

Revolution Medicines Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.35
Prev Close	$14.98
Open	$14.66
Dividend Yield	0.00%
50-Day Moving Average	$15.48
Beta	1.53
Avg. Volume	4.83M
PE Ratio	-15.03

52-Week High	$24.28
52-Week Low	$2.11
Market Capitalization	$5.02B
EPS (Annual)	-$0.4393
Price to Book	12.39
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ERAS Fundamentals